There have been a great progress in hematopoietic stem cell transplantation (SCT) for hematologic malignancies in various aspects including stem cell sources, supportive care, infrastructure, stem cell mobilization, etc., which has lead SCT from experimental therapy to standard medical practice. The most prominent is the advent of SCT with reduced-intensity conditioning (RIC) regimen. It has not only expanded the eligibility for SCT to patients of older age or with co-morbidities, but also highlighted the impact of graft-versus-tumor (GVT) effects in some malignant disorders such as follicular lymphoma, peripheral T-cell lymphoma, and chronic myeloid or lymphocytic leukemia. RIC will provide a possibility for myriads of newly developed molecular-targeted or antibody-based agents to be incorporated in SCT as pre- or post-SCT therapies.
|ジャーナル||Nihon rinsho. Japanese journal of clinical medicine|
|出版ステータス||Published - 2011 12 1|
ASJC Scopus subject areas